Strongest evidence: Outcomes with moderate evidence strength include improved irritable bowel syndrome (IBS) symptoms, reduced abdominal pain, and improved iron levels. For IBS symptoms, 3 of 4 studies reported beneficial effects, with one randomized controlled trial showing 95% of patients improved vs 15% on placebo; effect sizes were moderate to large, and the effective dose was 1×10^10 CFU/day. For abdominal pain, 3 of 4 studies found benefit, including complete resolution in one large RCT, but effect sizes were mixed. For iron levels, all 4 studies reported beneficial effects, with 3 being statistically significant, though doses were only specified in one trial (10^10 CFU/day).
Mixed or weaker evidence: Outcomes with low evidence strength include improved quality of life, bowel movement frequency, and reduced flatulence. For quality of life, 3 of 4 studies were beneficial but effect sizes ranged from small to large, and one well-controlled RCT showed neutral results. For bowel movement frequency, only 1 of 3 studies found a small benefit, while 2 were neutral, suggesting limited and inconsistent effects. For flatulence reduction, 2 of 3 studies were beneficial, but a large RCT (n=190) found no significant difference, and results are conflicting.
Effective dose patterns: Across multiple outcomes, a daily dose of 1×10^10 CFU emerges as the most commonly reported effective dose. This dose was specifically cited for IBS symptoms and quality of life, and doses of 1–2×10^10 CFU/day were used for flatulence reduction. Many studies on abdominal pain and iron levels did not report dosing, limiting dose conclusions for those outcomes.
Population insights: The most studied population is individuals with irritable bowel syndrome (IBS), appearing in outcomes for IBS symptoms, abdominal pain, bowel movement frequency, and flatulence. For iron levels, research focused on pregnant women and adults with iron deficiency anemia, while quality-of-life studies included patients with Hashimoto's thyroiditis, IBS, and cancer receiving home enteral nutrition. Generalizability to healthy populations is limited.
Notable caveats: The evidence base across all outcomes is small (3–4 studies each), making conclusions preliminary. Publication bias is a concern, as null-result studies may be underrepresented. Effect sizes varied widely (small to large) for many outcomes, and some outcomes (e.g., iron levels, quality of life) rely on specific populations, limiting broader application. Studies often lacked dose or duration reporting.